An Israeli startup that uses artificial intelligence to help manage treatment courses for diabetics has received a fifth clearance from the US Food and Drug Administration (FDA) for its endo.digital platform.
The new FDA clearance allows DreaMed to expand the scope of its recommended care plans for diabetics on a fixed regimen of insulin doses that are administered via pump or injection.
The endo.digital platform provides an automated total care plan for people with diabetes. The company says it is compatible with most devices used by diabetics to monitor their blood glucose levels and to administer insulin.
“As the shortage of diabetes experts persists globally, we continue to expand the use cases where we can unleash the power of AI to support patients and providers across all care settings,” said Prof. Moshe Phillip, DreaMed’s Chief Science Officer and the Director of the Endocrinology and Diabetes Institute at Schneider Children’s Medical Center.
Both DreaMed and Schneider are based in Petah Tikva.
“We are proud of our achievement to use AI to transform patient data into expert level treatment recommendations for yet another use case that meets FDA requirements,” Phillip said.
“As a company, we are not only expanding the addressable population for which we deliver value to customers, but also reducing the time it takes to get new FDA cleared use cases to market,” said DreaMed founder and CEO Eran Atlas.
“This is increasingly critical, as the market needs these solutions. In the U.S. alone, there are over 41,000 adults per endocrinologist, and more than 50 percent of all people with diabetes are not well managed due to limited access to proper care.”
Facebook comments